CNTA

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.30
Percentage change -1.78	%

Peers: VRTX REGN MRNA BMRN IONS ALNY SRPT NBIX INCY ZLAB

| Held by: IBB GWX ONEQ BBC BIB IBBQ FPXE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.53	Insider Own	31.53%	Shs Outstand	131.66M	Perf Week	-11.25%
Market Cap	2.18B	Forward P/E	-	EPS next Y	-1.55	Insider Trans	-1.53%	Shs Float	90.14M	Perf Month	-8.35%
Income	-162.05M	PEG	-	EPS next Q	-0.42	Inst Own	51.12%	Short Float	3.71%	Perf Quarter	0.67%
Sales	6.91M	P/S	315.72	EPS this Y	1.99%	Inst Trans	38.67%	Short Ratio	5.59	Perf Half Y	62.77%
Book/sh	3.79	P/B	4.37	EPS next Y	-0.73%	ROA	-32.83%	Short Interest	3.35M	Perf Year	149.17%
Cash/sh	3.94	P/C	4.21	EPS next 5Y	-	ROE	-42.73%	52W Range	6.29 - 18.97	Perf YTD	108.17%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-27.78%	52W High	-12.65%	Beta	1.54
Dividend TTM	-	Quick Ratio	21.52	Sales past 5Y	0.00%	Gross Margin	86.07%	52W Low	163.43%	ATR (14)	1.02
Dividend Ex-Date	-	Current Ratio	21.52	EPS Y/Y TTM	7.72%	Oper. Margin	-2350.25%	RSI (14)	46.60	Volatility	6.29% 6.93%
Employees	76	Debt/Eq	0.17	Sales Y/Y TTM	-	Profit Margin	-2344.26%	Recom	1.00	Target Price	28.57
Option/Short	Yes / Yes	LT Debt/Eq	0.17	EPS Q/Q	6.97%	Payout	-	Rel Volume	1.24	Prev Close	16.87
Sales Surprise	-	EPS Surprise	6.64%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	598.80K	Price	16.57
SMA20	-3.64%	SMA50	0.60%	SMA200	33.86%	Trades		Volume	742,112	Change	-1.78%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-20-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$11 → $26
Sep-19-24	Initiated	B. Riley Securities	Buy	$33
Jul-18-24	Initiated	Oppenheimer	Outperform	$14
Nov-15-23	Upgrade	Jefferies	Hold → Buy	$4 → $11
Oct-26-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$4 → $8
Jun-21-23	Initiated	Evercore ISI	Outperform
Jun-12-23	Initiated	Guggenheim	Buy	$9
Mar-17-23	Initiated	SVB Securities	Outperform	$6
Aug-12-22	Downgrade	Morgan Stanley	Overweight → Underweight	$10 → $5
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$19
Jun-03-22	Downgrade	Jefferies	Buy → Hold	$37 → $4
Feb-11-22	Initiated	Goldman	Neutral	$12

Show Previous Ratings

Nov-13-24 06:15AM	Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing (BioPharma Dive) +6.35%
Nov-12-24 07:00AM	Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update (GlobeNewswire)
Nov-04-24 07:30AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-12-24 10:18AM	Centessa Pharmaceuticals Plc (CNTA): A Small-Cap Leader in Clinical-Stage Biotech (Insider Monkey)
Oct-09-24 08:04AM	Analysts Rate Centessa Pharmaceuticals Plc (CNTA) as Strong Buy Amid Promising Developments (Insider Monkey)
06:00AM	Loading…
Sep-26-24 06:00AM	Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) (GlobeNewswire)
Sep-12-24 10:34PM	Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares (GlobeNewswire) +9.82% +12.52%
Sep-11-24 04:04PM	Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares (GlobeNewswire) -5.69%
Sep-10-24 04:34PM	Centessa Reverses Lower Despite $5 Billion Narcolepsy Opportunity (Investor's Business Daily)
12:19PM	Sleep-Disorder Focused Centessa Pharmaceuticals Unveils Interim Data From Lead Program In Acutely Sleep-Deprived Healthy Volunteers (Benzinga)
11:18AM	Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity (Investor's Business Daily)
08:15AM	Investors are waking up to Centessas sleepiness drug (BioPharma Dive)
07:00AM	Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers (GlobeNewswire)
Aug-27-24 08:00AM	Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) (GlobeNewswire)
Aug-24-24 01:18AM	Insider Sale: Chief Business Officer Gregory Weinhoff Sells 30,000 Shares of Centessa ... (GuruFocus.com)
08:00AM	Loading…
Aug-21-24 08:00AM	Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-13-24 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 (GlobeNewswire)
Jul-16-24 09:55AM	Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to Trade (Zacks)
Jun-13-24 09:00AM	The Lustgarten Foundation Appoints Two New Board Members (PR Newswire)
Jun-10-24 07:00AM	Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer (GlobeNewswire)
May-28-24 09:35AM	Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA) (Zacks)
May-21-24 08:45AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-13-24 09:54PM	CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
04:10PM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 (GlobeNewswire)
Apr-24-24 04:47AM	Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS (MT Newswires)
Apr-23-24 09:36PM	Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares (GlobeNewswire) -6.00%
06:00PM	Centessa Pharmaceuticals Eyes $100 Million in ADS Offering (MT Newswires)
04:17PM	Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares (GlobeNewswire)
Apr-22-24 07:00AM	Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 (GlobeNewswire) -5.39%
Mar-28-24 11:53PM	CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
06:11PM	Loading…
06:11PM	Centessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 Results (GuruFocus.com)
04:28PM	Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 (GlobeNewswire)
Mar-27-24 01:26AM	Centessa Pharmaceuticals PLC Chief People Officer Sells Company Shares (GuruFocus.com)
Mar-18-24 08:01PM	7 Biotech Stocks Ready to Ride the Sectors Resurgence (InvestorPlace) +5.18%
Feb-22-24 08:00AM	Centessa Pharmaceuticals to Participate in TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Feb-09-24 07:00AM	Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) (GlobeNewswire) +24.13%
Jan-22-24 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Dec-13-23 08:00AM	Centessa Pharmaceuticals to Present at the 42 Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-23 12:05PM	Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia (GlobeNewswire)
Dec-05-23 09:55AM	Does Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) Have the Potential to Rally 40.85% as Wall Street Analysts Expect? (Zacks)
Nov-27-23 04:15PM	Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals (GlobeNewswire) -7.69%
Nov-16-23 09:55AM	Wall Street Analysts Predict a 35.92% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know (Zacks)
Nov-14-23 07:28PM	Centessa Pharmaceuticals PLC Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) +6.25% +8.75%
Nov-13-23 04:05PM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023 (GlobeNewswire)
Nov-02-23 09:09AM	Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-23 08:00AM	Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors (GlobeNewswire)
Oct-30-23 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.32%
Oct-25-23 08:00AM	Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750's Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders (GlobeNewswire) -6.02%
Oct-03-23 08:00AM	Centessa Pharmaceuticals Announces Additions to Senior Leadership Team (GlobeNewswire)
Sep-04-23 10:51AM	Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why (Zacks)
Aug-31-23 08:00AM	Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire) +6.35%
Aug-23-23 05:08PM	Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress (GlobeNewswire)
Aug-14-23 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023 (GlobeNewswire)
Jul-10-23 08:00AM	Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors (GlobeNewswire) +5.04%
May-24-23 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-22-23 07:00AM	Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B (GlobeNewswire)
May-12-23 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023 (GlobeNewswire)
Apr-27-23 12:07PM	Centessa Pharmaceuticals plc (NASDAQ:CNTA) most popular amongst private equity firms who own 42% of the shares, institutions hold 22% (Simply Wall St.) -5.71%
Mar-30-23 07:00AM	Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022 (GlobeNewswire)
Mar-27-23 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-23-23 04:30PM	Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director (PR Newswire) +5.04%
08:32AM	Should You Buy Centessa Pharmaceuticals (CNTA) Ahead of Earnings? (Zacks)
Mar-01-23 08:00AM	Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines (GlobeNewswire)
Feb-06-23 08:00AM	Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) (GlobeNewswire)
Feb-02-23 08:00AM	Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-26-23 09:08AM	Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors (GlobeNewswire)
Dec-10-22 03:30PM	Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia (GlobeNewswire)
Nov-30-22 08:00AM	Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson (GlobeNewswire)
Nov-18-22 10:29AM	While institutions own 29% of Centessa Pharmaceuticals plc (NASDAQ:CNTA), private equity firms are its largest shareholders with 42% ownership (Simply Wall St.)
Nov-10-22 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022 (GlobeNewswire)
Nov-03-22 09:04AM	Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting (GlobeNewswire)
Oct-31-22 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-20-22 08:33AM	Centessa Pharmaceuticals Announces Poster Presentation Featuring Novel Orexin Receptor 2 (OX2R) Agonist Discovery Pipeline at the 26th Conference of the European Sleep Research Society (Sleep Europe 2022) (GlobeNewswire)
Sep-14-22 09:00AM	Centessa Pharmaceuticals Announces Orphan Drug Designation Granted to SerpinPC for the Treatment of Hemophilia B (GlobeNewswire) +8.92%
Sep-12-22 07:00AM	Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index (GlobeNewswire)
Aug-29-22 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-22 08:37AM	Centessa Culls Early-Stage Asset For Inherited Disorder (Benzinga) -5.19%
06:30AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874 (GlobeNewswire)
Jul-29-22 05:00AM	Why are Massachusetts CEOs paid so much money? Here's a primer (American City Business Journals)
Jul-25-22 08:00AM	Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs (GlobeNewswire)
Jul-01-22 08:40AM	Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors (GlobeNewswire) +6.16%
Jun-23-22 09:55AM	Wall Street Analysts Predict a 128% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know (Zacks)
Jun-17-22 02:35PM	BMO Capital Sees Almost 300% Upside On Centessa Stock (Benzinga) +19.08%
Jun-11-22 10:06AM	What Kind Of Investors Own Most Of Centessa Pharmaceuticals plc (NASDAQ:CNTA)? (Simply Wall St.)
Jun-06-22 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-05-22 07:00AM	Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting (GlobeNewswire)
Jun-03-22 08:29AM	Record-Setting Biotech Plunges 25% After Axing Lead Program (TheStreet.com)
Jun-02-22 06:29AM	Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) (GlobeNewswire) -27.78%
May-16-22 07:00AM	Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-30-22 04:01PM	Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-23-22 04:30PM	Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day (GlobeNewswire)
Mar-07-22 07:30AM	Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise (GlobeNewswire)
Feb-24-22 07:30AM	Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease (GlobeNewswire)
Feb-17-22 02:38AM	Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs Samsara BioCapital (Insider Monkey)
Jan-01-22 07:33AM	Do Institutions Own Centessa Pharmaceuticals Limited (NASDAQ:CNTA) Shares? (Simply Wall St.)
Dec-21-21 06:38PM	Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ... (GuruFocus.com) +10.06%
Dec-14-21 07:30AM	Centessa Pharmaceuticals Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease, Reports Initial Positive Safety Data from ALERT Study, and Announces Notice of Allowance for Key Lixivaptan U.S. Patent Application (GlobeNewswire) -9.39%
Dec-13-21 04:15PM	Centessa Pharmaceuticals Announces Addition to NASDAQ Biotechnology Index (GlobeNewswire)
Dec-06-21 05:00PM	2 Big Stock Bets That Are Insiders Are Buying Now (InvestorPlace) -5.58% +9.08%
Nov-24-21 06:59AM	Centessa Pharmaceuticals (CNTA) Sees Hammer Chart Pattern: Time to Buy? (Zacks)

Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. Its portfolio include preclinical to phase three uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. The company was founded on October 26, 2020 and is headquartered in Altrincham, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Anderson Karen M.	Officer	Dec 13 '24	Proposed Sale	16.89	16,500	278,685		Dec 13 04:03 PM
SAHA SAURABH	Chief Executive Officer	Dec 06 '24	Option Exercise	5.84	87,496	510,977	663,157	Dec 06 05:03 PM
SAHA SAURABH	Chief Executive Officer	Dec 06 '24	Sale	18.46	87,496	1,615,255	575,661	Dec 06 05:03 PM
SAHA SAURABH	Officer	Dec 06 '24	Proposed Sale	18.46	87,496	1,615,255		Dec 06 04:14 PM
SAHA SAURABH	Chief Executive Officer	Nov 25 '24	Option Exercise	5.84	299	1,746	575,960	Nov 27 04:22 PM
SAHA SAURABH	Chief Executive Officer	Nov 25 '24	Sale	18.23	299	5,451	575,661	Nov 27 04:22 PM
Weinhoff Gregory M	Chief Business Officer	Nov 25 '24	Option Exercise	3.85	10,000	38,500	193,266	Nov 27 04:20 PM
Weinhoff Gregory M	Chief Business Officer	Nov 25 '24	Sale	17.66	10,000	176,601	183,266	Nov 27 04:20 PM
Weinhoff Gregory M	Officer	Nov 25 '24	Proposed Sale	17.39	10,000	173,900		Nov 25 04:07 PM
SAHA SAURABH	Officer	Nov 25 '24	Proposed Sale	34.95	299	10,451		Nov 25 04:03 PM
SAHA SAURABH	Chief Executive Officer	Nov 21 '24	Option Exercise	5.84	3,511	20,504	579,172	Nov 22 05:06 PM
SAHA SAURABH	Chief Executive Officer	Nov 22 '24	Option Exercise	5.84	1,671	9,759	577,332	Nov 22 05:06 PM
SAHA SAURABH	Chief Executive Officer	Nov 20 '24	Sale	16.89	55,000	928,719	575,661	Nov 22 05:06 PM
SAHA SAURABH	Chief Executive Officer	Nov 21 '24	Sale	18.24	3,511	64,028	575,661	Nov 22 05:06 PM
SAHA SAURABH	Chief Executive Officer	Nov 22 '24	Sale	18.24	1,671	30,478	575,661	Nov 22 05:06 PM
SAHA SAURABH	Officer	Nov 22 '24	Proposed Sale	18.23	1,671	30,462		Nov 22 04:03 PM
SAHA SAURABH	Officer	Nov 21 '24	Proposed Sale	18.24	3,511	64,028		Nov 21 04:33 PM
SAHA SAURABH	Officer	Nov 20 '24	Proposed Sale	16.97	55,000	933,350		Nov 20 04:03 PM
SAHA SAURABH	Chief Executive Officer	Nov 13 '24	Option Exercise	5.84	32,023	187,014	662,684	Nov 15 04:30 PM
SAHA SAURABH	Chief Executive Officer	Nov 13 '24	Sale	18.28	32,023	585,419	630,661	Nov 15 04:30 PM
SAHA SAURABH	Officer	Nov 13 '24	Proposed Sale	18.28	32,023	585,418		Nov 13 04:18 PM
Weinhoff Gregory M	Chief Business Officer	Oct 25 '24	Sale	15.38	11,742	180,628	183,266	Oct 25 07:19 PM
Weinhoff Gregory M	Officer	Oct 25 '24	Proposed Sale	15.57	11,742	182,822		Oct 25 04:10 PM
SAHA SAURABH	Chief Executive Officer	Oct 22 '24	Sale	15.67	30,203	473,169	633,253	Oct 23 05:27 PM
SAHA SAURABH	Chief Executive Officer	Oct 21 '24	Sale	15.80	22,205	350,861	663,456	Oct 23 05:27 PM
SAHA SAURABH	Chief Executive Officer	Oct 23 '24	Sale	15.32	2,592	39,697	630,661	Oct 23 05:27 PM
SAHA SAURABH	Officer	Oct 23 '24	Proposed Sale	15.46	2,592	40,072		Oct 23 04:07 PM
SAHA SAURABH	Officer	Oct 22 '24	Proposed Sale	15.67	30,203	473,169		Oct 22 04:15 PM
SAHA SAURABH	Officer	Oct 21 '24	Proposed Sale	15.80	22,205	350,861		Oct 21 04:55 PM
Weinhoff Gregory M	Chief Business Officer	Sep 25 '24	Sale	15.69	16,619	260,724	206,750	Sep 27 04:15 PM
Weinhoff Gregory M	Officer	Sep 25 '24	Proposed Sale	15.80	16,619	262,580		Sep 25 04:01 PM
SAHA SAURABH	Chief Executive Officer	Sep 20 '24	Sale	16.53	55,000	908,985	721,924	Sep 20 04:55 PM
SAHA SAURABH	Officer	Sep 20 '24	Proposed Sale	16.45	55,000	904,750		Sep 20 04:01 PM
Weinhoff Gregory M	Chief Business Officer	Sep 10 '24	Option Exercise	5.84	30,000	175,200	253,369	Sep 12 08:01 PM
Weinhoff Gregory M	Chief Business Officer	Sep 10 '24	Sale	17.00	30,000	510,000	223,369	Sep 12 08:01 PM
SAHA SAURABH	Chief Executive Officer	Sep 10 '24	Option Exercise	5.84	175,000	1,022,000	951,924	Sep 12 08:01 PM
SAHA SAURABH	Chief Executive Officer	Sep 10 '24	Sale	16.52	175,000	2,891,822	776,924	Sep 12 08:01 PM
SAHA SAURABH	Officer	Sep 10 '24	Proposed Sale	16.52	175,000	2,891,822		Sep 10 04:06 PM
Weinhoff Gregory M	Officer	Sep 10 '24	Proposed Sale	17.00	30,000	510,000		Sep 10 04:04 PM
Weinhoff Gregory M	Chief Business Officer	Sep 09 '24	Option Exercise	5.84	25,000	146,000	248,369	Sep 09 05:06 PM
Weinhoff Gregory M	Chief Business Officer	Sep 09 '24	Sale	15.00	25,000	375,000	223,369	Sep 09 05:06 PM
Weinhoff Gregory M	Officer	Sep 09 '24	Proposed Sale	15.00	25,000	375,000		Sep 09 04:07 PM
SAHA SAURABH	Chief Executive Officer	Aug 23 '24	Sale	12.30	46,651	573,905	776,924	Aug 23 05:13 PM
Weinhoff Gregory M	Chief Business Officer	Aug 23 '24	Sale	12.29	17,802	218,792	223,369	Aug 23 05:12 PM
Weinhoff Gregory M	Chief Business Officer	Aug 22 '24	Sale	12.17	12,198	148,430	241,171	Aug 23 05:12 PM
Weinhoff Gregory M	Officer	Aug 23 '24	Proposed Sale	12.29	17,802	218,792		Aug 23 04:19 PM
SAHA SAURABH	Officer	Aug 23 '24	Proposed Sale	12.30	46,651	573,905		Aug 23 04:13 PM
SAHA SAURABH	Chief Executive Officer	Aug 20 '24	Sale	12.32	4,169	51,368	827,755	Aug 22 05:15 PM
SAHA SAURABH	Chief Executive Officer	Aug 21 '24	Sale	12.25	3,674	44,989	824,081	Aug 22 05:15 PM
SAHA SAURABH	Chief Executive Officer	Aug 22 '24	Sale	12.23	506	6,188	823,575	Aug 22 05:15 PM
Weinhoff Gregory M	Officer	Aug 22 '24	Proposed Sale	12.24	12,198	149,304		Aug 22 04:32 PM
SAHA SAURABH	Officer	Aug 22 '24	Proposed Sale	12.23	506	6,188		Aug 22 04:13 PM
SAHA SAURABH	Officer	Aug 21 '24	Proposed Sale	12.25	3,674	44,989		Aug 21 04:38 PM
SAHA SAURABH	Officer	Aug 20 '24	Proposed Sale	12.32	4,169	51,368		Aug 20 04:52 PM
Anderson Karen M.	Chief People Officer	Mar 25 '24	Option Exercise	3.94	45,000	177,252	122,685	Mar 26 04:16 PM
Anderson Karen M.	Chief People Officer	Mar 25 '24	Sale	11.88	51,160	607,960	71,525	Mar 26 04:16 PM
Rotman Harris	SVP Regulatory Affairs	Feb 01 '24	Sale	8.10	4,267	34,574	62,625	Feb 02 05:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Centessa Pharmaceuticals plc ADR

Upgrade your FINVIZ experience